Archive for biotech

Syntrix Wins U.S. Patent 9,000,142: Photocleavable Sense-Antisense Complex

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventor:  Zebala; John A. (Sammamish, WA) Abstract:  There is disclosed a photocleavable sense-antisense nucleobase polymer complex capable of modulating gene expression comprising an unnatural antisense nucleobase polymer that targets an mRNA, and a photocleavable sense nucleobase polymer noncovalently […]

Syntrix Wins U.S. Patent 8,993,541: Aminopyrimidine Carboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); Zebala, John A. (Sammamish, WA); and Schuler, Aaron D. (Auburn, WA).  Abstract: There are disclosed aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyrimidinecarboxamides compounds. More specifically, […]

Syntrix Wins U.S. Patent 8,981,106: Pyrimidinecarboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); and Zebala, John A. (Sammamish, WA).  Abstract: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there […]

Syntrix Wins U.S. Patent 8,969,365: Thiopyrimidinecarboxamides as CXCR1/2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); Zebala, John A. (Sammamish, WA); and Schuler, Aaron D. (Auburn, WA).  Abstract: There is disclosed a pyrimidinecarboxamide compound useful as a pharmaceutical agent, synthetic processes, and pharmaceutical compositions which include the pyrimidinecarboxamide […]

Syntrix Featured in the NIH Innovation Zone at 2014 Bio International Convention in San Diego, CA

Syntrix was selected by the NIH to host a kiosk in the Innovation Zone, an area dedicated to showcasing Small Business Innovation Research (SBIR) grantees.  In addition, Syntrix was granted an additional opportunity to present their innovative research at the NIH Booth located in Hall A of the Discovery Zone.  The Syntrix presentation featured SX-682, […]

Syntrix Presents at the 2014 ACA Summit in Washington, D.C.

Syntrix was invited to present at the 2014 Angel Capital Association (ACA) Summit co-sponsored by the National Heart Lung and Blood Institute (NHLBI).  This conference brings together businesses, angel investors, and strategic partners from the biotech and pharmaceutical industries. It features presentations by top NHLBI-funded companies with innovative technologies.  The Syntrix presentation featured SX-682, the […]

Syntrix Presents at the 2013 NHLBI Innovation Conference in San Francisco

Syntrix was one of six breakthrough technology companies invited to present at the 2013 Innovation Conference sponsored by the National Heart Lung and Blood Institute (NHLBI).  This conference brings together businesses, investors, and strategic partners from the biotech and pharmaceutical industries. It features presentations by top NHLBI-funded companies with innovative technologies.  The Syntrix presentation featured […]

Dr. Zebala Invited to Speak at the 2011-2012 David Rogers Health Policy Colloquium at the Weill Cornell Medical College

Dr. John Zebala, President and CEO of Syntrix Biosystems and alumnus of the Weill Cornell Medical College was an invited speaker at the 2011-2012 David E. Rogers Health Policy Colloquium. Dr. Zebala shared his experience with the current business and regulatory challenges facing early-stage drug development. Learn more about the life of David E. Rogers. 

Collaboration: Syntrix Receives $557K Grant to Develop New Drug for Multiple Drug Resistant Tuberculosis

Syntrix scientists will collaborate with Dr. Andrew Bognar of the University of Toronto on a $557K tuberculosis grant from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The project title is “Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB.” The public health relevance from the proposal: “Multidrug-resistant tuberculosis and extensively drug […]

Syntrix Featured in Microsoft Case Study on Technology Development for Spatiotemporal Gene Control

Syntrix research and development program toward developing a spatiotemporal gene control technology was featured in a Microsoft Case Study. Read the article.